What does Medite Cancer Diagnostics, Inc. do?

Medite Cancer Diagnostics, Inc. (MDIT) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is MDIT's market cap?

Medite Cancer Diagnostics, Inc. (MDIT) has a market capitalization of approximately $8,672, as of August 25, 2026, based on the most recent share price and shares outstanding.

Does MDIT pay a dividend?

No — Medite Cancer Diagnostics, Inc. (MDIT) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Medite Cancer Diagnostics, Inc. (MDIT) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

MDIT

Medite Cancer Diagnostics, Inc.

OTC·Medical, Instruments & Supplies · Healthcare

$0.00$0.00+0.00%

Market cap$8.67K·Market closed·Aug 25 8:00 PM UTC

Price Chart

$0.00+$0.00 (+0.00%)today

−99.38%CAGR −63.77%

Select date range

FromTo

Feb 2, 1995Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

MDIT does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateFeb 26

Last Report DateNov 14

Reported vs Estimate−$0.01

Earnings Surprise—

Income Statement Flow

PRO

See exactly how MDIT's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MDIT and 80,000+ other tickers.

About Medite Cancer Diagnostics, Inc.

Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing…

CEO: Rahsan-Rahsan Lindsay
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Exchange: OTC
Employees: 69
Website: medite-group.com

Peers

Peers Tab

ASFX

American Scientific Resources, Incorporated

Cap

$5.3K

SCPS

Scopus BioPharma Inc.

Latest News

News Tab

No recent news available.

Frequently Asked Questions About MDIT

What does Medite Cancer Diagnostics, Inc. do?: Medite Cancer Diagnostics, Inc. (MDIT) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is MDIT's market cap?: Medite Cancer Diagnostics, Inc. (MDIT) has a market capitalization of approximately $8,672, as of August 25, 2026, based on the most recent share price and shares outstanding.
Does MDIT pay a dividend?: No — Medite Cancer Diagnostics, Inc. (MDIT) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is MDIT profitable?: Medite Cancer Diagnostics, Inc. (MDIT) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.